In an interview, Scholar Rock's chief medical officer talks about benefits seen in clinical trials of its muscle-targeted SMA ...

Roche had appealed against a single judge order of March 24 that had refused to stop Natco Pharma from manufacturing a generic version of Risdiplam ...

"Roche has filed an appeal against the Hon. Delhi High Court order and the matter is subjudice in the appeal court," Roche ...

The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.

The bench said that public good outweighs the company’s profit as the drug is not available at an affordable price in India.

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

NASA Astronaut Sunita Williams has returned to Earth after spending over 9 moths in space - under microgravity. Even though ...

Bone Density Loss: Prolonged exposure to microgravity can also lead to decreased bone density, increasing the risk of fractures. Research indicates that astronauts can lose around 1% of their bone ...

The realm of outer space has long fascinated humanity, but it also holds significant challenges, especially concerning human health. Recently, the return of two astronauts who spent nine months in ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Activating a protein called potassium channel Kv2.1 may help improve motor function in SMA, making it a potential SMA ...